Clinical effect of Ropivacaine combined with oxycodone on paravertebral nerve block

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075548

Enrollment

Unknown

Registered

2023-09-08

Start date

2022-09-20

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Blank control group:Simple intravenous analgesia

Ropivacaine group:Ropivacaine for paravertebral nerve block+intravenous analgesia

Oxycodone group:Oxycodone for paravertebral nerve block+intravenous analgesia

Ropivacaine combined with oxycodone group:Ropivacaine combined with oxycodone for paravertebral nerve block+intravenous analgesia

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 40~65 years old; 2.National Association of Anesthesiologists (ASA) Grade ?~?; 3.Body weight 40~80kg; 4.Elective thoracoscopic unilateral lobectomy.

Exclusion criteria

Exclusion criteria: 1.transthoracotomy; 2.Multiple lobectomy or bilateral lobectomy; 3.Liver and kidney insufficiency; 4.Contraindications of thoracic paravertebral nerve block: local skin infection, coagulation dysfunction, etc; 5.Mental illness or other reasons for inability to cooperate; 6.Severe hypertension, diabetes, etc; 7.Have received chemoradiotherapy; 8.A history of opioid abuse; 9.People who refuse to participate.

Design outcomes

Primary

Measure	Time frame
Visual analog scale (VAS);	—

Secondary

Measure	Time frame
HR;MAP;Ramsay sedation score;Cortisol;TNF-a;Number of effective compressions of analgesic pump;Remedial analgesia;	—

Countries

China

Contacts

Public ContactJia Min

The First Affiliated Hospital of Nanchang University

candymin66@163.com+86 139 7089 9291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026